Compare Southern Copper Corp (SCCO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Tango Therapeutics Inc. — how do they compare? Southern Copper Corp trades at $197 (market cap $175.13B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Southern Copper Corp is far larger — about 46.7× Tango Therapeutics Inc.'s market cap, and Southern Copper Corp pays a 2.12% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 62 Days and Tango Therapeutics Inc. for 0 Days on average.
| SCCO | TNGX | |
|---|---|---|
Market Cap | $175.13B | $3.75B |
Volume | 611,484 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $32.90 |
52-Week Low | $120.02 | $7.50 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $176.43B | $2.77B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $200.68, down 3.84% on the day, but maintains strong fundamentals with impressive earnings beats and robust profitability metrics. The company shows consistent revenue growth from $10.0B in 2022 to $13.4B in 2025, with net income margins expanding to 35.87%. Technical indicators show a bullish trend with support at $204 and resistance at $210, while analyst sentiment remains divided with a consensus price target of $165.60.
SCCO presents a mixed investment case with exceptional profitability and growth prospects from its Mexican projects, but faces valuation concerns with a P/E of 31.12 and divided analyst ratings. Key risks include copper price volatility and execution challenges, while institutional interest remains active with recent purchases by Virginia Retirement Systems.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
